In apolipoprotein E-deficient mice model, CCL4 antibody treatment reduced circulating IL-6 and TNF-α whereby the authors concluded that CCL4 inhibition seems to be a promising tool within the box of anti-inflammatory therapeutics in patients diagnosed with atherosclerosis [46]. This evidence concerns the gene CCL4 and atherosclerosis.